For patients with EGFR PACC-mutated non-small cell lung cancer (NSCLC), the targeted therapy firmonertinib achieved durable antitumor activity in a Phase Ib trial led by researchers at The University of Texas MD Anderson Cancer Center, supporting an approach to selecting...
Urinary L-FABP predicted eGFR decline and persistent albuminuria before UACR adjustment; however, both associations disappeared after adjustment for continuous baseline UACR, indicating that quantita To the Editor, Estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR) are the principal...
D2C7-ATC is a recombinant antibody−toxin conjugate (ATC) targeting wild-type epidermal growth factor receptor (EGFR) and mutant EGFR variant III (EGFRvIII). We conducted a single-arm, single-site, open-label phase 1 trial evaluating a single infusion of D2C7-ATC via convection-enhanced delivery in the...
PerspectiveEfforts toward Equity Share on Disparities in Kidney Disease and the Race-Neutral eGFR - Research and Action in NYC’s Public Hospital SystemAuthors: Angelica Bocour, M.P.H., Erin Lewis, M.D., Silas Lee, M.S., and Leo G. Eisenstein, M.D. https://orcid.org/0000-0003-4714-6990Author Info & AffiliationsPublished...
Abstract In non-small cell lung cancer (NSCLC), EGFR and HER2 mutations are generally considered mutually exclusive events, with a co-occurrence probability estimated to be less than 1%. Patients with either EGFR or HER2 mutations tend to exhibit low PD-L1 expression...
BackgroundAntibody–drug conjugates (ADCs) have emerged as potential treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine Abstract Background: Antibody–drug conjugates (ADCs) have emerged as potential treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor...
AENEAS2: Aumolertinib Plus Chemotherapy Extends PFS in EGFR-Mutant Advanced NSCLC First-line treatment for EGFR-mutated advanced non-small-cell lung cancer (NSCLC) continues to evolve from EGFR tyrosine kinase inhibitor (TKI) monotherapy toward more intensive strategies designed to delay acquired resistance and prolong...
AbstractBackground Cardiovascular toxicity has been reported during treatment with osimertinib, but evidence for other third-generation EGFR tyrosine kinase inhibitors remains limited. Whether similar cardiovascular abnormalities occur during treatment with different agents in this class remains uncertain. We investigated the incidence,...
AbstractBackground People living with HIV (PLWH) remain at risk of kidney dysfunction, making the assessment of glomerular filtration an component of HIV care. However, both creatinine- and cystatin C-based estimated glomerular filtration rate (eGFR) are influenced by non-GFR determinants, and...
